http://jcps.bjmu.edu.cn

• Review • Previous Articles     Next Articles

GLP-1 biology and GLP-1 based antidiabetic therapy

Fan Yi, Dong Li, Weizhi Ma, Quan Du*   

  1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2013-01-08 Revised:2013-01-15 Online:2013-01-20 Published:2013-01-20
  • Contact: Quan Du*

Abstract:

Environmental and lifestyle factors together account for the dramatic increase of type 2 diabetes in the past decades, in which defective insulin secretion emerges as the major culprit. Glucagon-like peptide 1 (GLP-1) is a peptide secreted from the intestine in response to nutrient ingestion, and plays an essential role in the regulation of blood glucose level by stimulating glucoses-dependent insulin secretion. Recently, GLP-1 develops to be a viable therapeutic target for the treatment of type 2 diabetes, by means of GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Stemmed from its potent physiological activities, GLP-1-based therapies are clinically efficient and safe for both early and late stages of the disease, with low risk of adverse events. In this review, a comprehensive understanding of GLP-1 biology and the recent development of GLP-1-based antidiabetic therapy are summarized.

Key words: GLP-1, GLP-1 receptor, Diabetes, Incretin hormones

CLC Number: 

Supporting: